Stay tuned for more details, coming soon.
Carolina Aguilar is CEO and Co-Founder of INBRAIN Neuroelectronics, a BCI therapeutics company pioneering real time precision neurology through the development of high density graphene brain interfaces with unparalleled decoding resolution and micrometric precision modulation with the mission to decode neural signals to improve people’s lives
She has over 20 years of expertise in healthcare out of which she was 13 years in the European Headquarters of Medtronic in Switzerland, leading globally businesses in brain modulation and diabetes where she managed complex markets and large teams that generated high YoY growth and innovation. Carolina is passionate about creating solutions that improve the outcomes that matter to patients and drive healthcare sustainability. Her leadership in Diabetes at the Diabeter clinics contributed to the creation of a Harvard Business School Case at Medtronic and a major expansion in Saudi Arabia and Spain with payments made on outcomes. INBRAIN just published its 5th NATURE paper and in 2023 got FDA breakthrough designation for their innovative neural platform. Last year it also delivered the world's firsts application of a graphene-based neural interface in humans. The company also won the Most Innovative Company of the Year in 2022 and the Norrsken IMPACT 100 award in 2024, and it’s the second best out of the top 100 world’s BCI companies according to Dealroom in April 2025
